We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、神戸天然物化学株式会社（本社：神戸市、代表取締役社長：真岡宅哉）及び神戸信用金庫（本店：神戸市、代表理事：西多弘行）を...
[画像1: https://prtimes.jp/i/125161/5/resize/d125161-5-29ba4ba02349f2a0e961-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、株式会社神戸大学キャピタル（KUC1...
[画像1: https://prtimes.jp/i/125161/3/resize/d125161-3-864079061e220d758061-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、大阪大学ベンチャーキャピタル株式...
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、下記を引受先とする第三者割当増資を行い、シードラウンドBとして総額1億400万円を2023年7月に調達したことを報告いたします。...
Development and sales of solutions for preventing the worsening of diabetes complications.
Elcyo develops innovative autofocal glasses that automatically adjust focus with proprietary lens technology. Leveraging Fresnel Liquid Crystal Lens Technology, Elcyo has made it possible to create glasses that maintain focus at any distance, addressing a wide range of vision challenges across healthcare, entertainment, and beyond.
A startup developing medical devices that diagnose and treat sleep-disordered breathing using non-contact sensing and digital signal processing technology. We provide a new sleep monitoring solution that requires no wearable devices, minimizes burden, and respects privacy.
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
